Short peptide includes the functional segment of RA-specific protein

Our Innovation

The therapeutic RA-peptide restrictively reduces the pathological activity of joint inflammation, which destroys the bone and the cartilage, using a novel mechanism of action.  As innocent tissues and cells should be only minimally affected by this drug, it may cause limited number of side effects, as compared to known RA approved drugs.

Highlights

• Short peptide that includes the functional segment of the RA-specific protein and therefore may display, by a competition, a disease-blocking activity.
• Development of a therapeutic peptide is much shorter and cheaper than- therapeutic antibodies, and may be completed within 3 to 5 years.
• Current RA drugs are non specific and generate severe complications in some patients.

Key Features

• While all approved RA drugs are administrated via injections, a wider possibilities of formulation and modes of administration are existing for peptides, e.g., topically (as an ointment), or orally (as a tablet).
• Development and production cost of peptides is much lower than for monoclonal antibodies.
• The mechanism of action of RA-Peptide is based on blocking of disease specific protein, which is expressed locally in the joints of RA patients and engaged in the destructive pathological activity detected in the bone and the cartilage. Therefore, the disease-specific protein can be used as a target for the therapeutic peptide.

Development Milestones

Seeking funding for ongoing research and preclinical studies

The Opportunity

Also applicable for psoriatic arthritis (PsA) which affects 4 million people in the seven major pharmaceutical markets.

Granted US 8,193,311